Participate in either the ‘Target Discovery & In Vitro Validation’, ‘In Vivo Translation & Early Clinical’ or ‘Late Clinical, Regulatory & Commercial’ stream of the main conference days to ensure your time out of the office is completely relevant to your priorities and expertise.

Enhance clinical utility of plasma-based β-Amyloid markers with Biogen, Takeda and Eisai, elevate p-tau assay sensitivity with Johnson & Johnson, and advance the α-synuclein SAA with Michael J Fox Foundation.

Engage with patients and prescribing neurologists to navigate the uptake of novel anti-amyloids and understand their needs from the next wave of neurodegenerative therapeutics and clinical trials.

40+ brand-new speakers including fresh perspectives from Eli Lilly, Bristol Myers Squibb, Novartis and AbbVie, and 12+ new presenting companies including Annovis Bio, Lundbeck and Lexeo Therapeutics.

Stay at the forefront of new programs targeting tau, TDP-43 and APOE4, review progress of GLP-1s, and discover next-generation technologies to enhance brain penetrance with Roche and AC Immune.